MAPT and Alzheimer disease: While the serum treatment approach successfully induces a subset of key features of AD pathology including amyloid-β aggregation, tau phosphorylation, synaptic loss, and neuroinflammation as demonstrated in the original Chen et al. study, it lacks the established AD-specificity of genetic models involving familial AD mutations.